HIV requires multiple gp120 molecules for CD4-mediated infection

[1]  J. Moore.  Simple methods for monitoring HIV-1 and HIV-2 gp120 binding to soluble CD4 by enzyme-linked immunosorbent assay: HIV-2 has a 25-fold lower affinity than HIV-1 for soluble CD4. , 1990, AIDS.

[2]  J. Goudsmit,et al.  Predominance of HIV-1 serotype distinct from LAV-1/HTLV-IIIB , 1990, The Lancet.

[3]  R. Schooley,et al.  Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. , 1990, Annals of internal medicine.

[4]  T. L. Hodges,et al.  The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study. , 1990, Annals of internal medicine.

[5]  J. Groopman,et al.  Characterization of in vitro inhibition of human immunodeficiency virus by purified recombinant CD4 , 1989, Journal of virology.

[6]  K. M. Hwang,et al.  CD4 antigen-based antireceptor peptides inhibit infectivity of human immunodeficiency virus in vitro at multiple stages of the viral life cycle. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[7]  T. H. Lee,et al.  Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120 , 1989, Journal of virology.

[8]  Michael Emerman,et al.  Single amino-acid changes in HIV envelope affect viral tropism and receptor binding , 1989, Nature.

[9]  J. Spouge,et al.  Quantifying the infectivity of human immunodeficiency virus. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[10]  K. Karjalainen,et al.  Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules , 1989, Nature.

[11]  H. Mitsuya,et al.  Designing CD4 immunoadhesins for AIDS therapy , 1989, Nature.

[12]  A. Dalgleish,et al.  Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells , 1989, Nature.

[13]  N. Letvin,et al.  Effect of recombinant soluble CD4 in rhesus monkeys infected with simian immunodeficiency virus of macaques , 1989, Nature.

[14]  G. Shaw,et al.  Extensive variation of human immunodeficiency virus type-1 in vivo , 1988, Nature.

[15]  R. Redfield,et al.  Type-restricted neutralization of molecular clones of human immunodeficiency virus. , 1988, Science.

[16]  K. Steimer,et al.  Internalization of the human immunodeficiency virus does not require the cytoplasmic domain of CD4 , 1988, Nature.

[17]  P. Nara,et al.  Quantitative infectivity assay for HIV-1 and -2 , 1988, Nature.

[18]  Gilcher Ro.  Human retroviruses and AIDS. , 1988 .

[19]  W. Lüke,et al.  Soluble CD4 molecules neutralize human immunodeficiency virus type 1 , 1988, Nature.

[20]  B. Walker,et al.  HIV infection is blocked in vitro by recombinant soluble CD4 , 1988, Nature.

[21]  R. Axel,et al.  soluble form of CD4 (T4) protein inhibits AIDS virus infection , 1988, Nature.

[22]  R. Siliciano,et al.  A soluble CD4 protein selectively inhibits HIV replication and syncytium formation , 1988, Nature.

[23]  S. Marsters,et al.  Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen. , 1987, Science.

[24]  J. Sodroski,et al.  Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. , 1987, Science.

[25]  G. Nakamura,et al.  Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor , 1987, Cell.

[26]  N. Dimmock,et al.  Quantitative relationships between an influenza virus and neutralizing antibody. , 1987, Virology.

[27]  Robert Tibshirani,et al.  Bootstrap Methods for Standard Errors, Confidence Intervals, and Other Measures of Statistical Accuracy , 1986 .

[28]  J K Nicholson,et al.  Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule. , 1986, Science.

[29]  E. Wimmer,et al.  Bivalent attachment of antibody onto poliovirus leads to conformational alteration and neutralization , 1983, Journal of virology.

[30]  R. Rueckert,et al.  Neutralization of poliovirus by a monoclonal antibody: kinetics and stoichiometry. , 1983, Virology.

[31]  Maurice G. Kendall,et al.  The advanced theory of statistics , 1945 .

[32]  P. Earl,et al.  Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. Spouge,et al.  Analytic results for quantifying HIV infectivity , 1989 .

[34]  M. Gonda,et al.  Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody. , 1987, AIDS research and human retroviruses.

[35]  L. Arthur,et al.  Purification of 120,000 dalton envelope glycoprotein from culture fluids of human immunodeficiency virus (HIV)-infected H9 cells. , 1987, AIDS research and human retroviruses.

[36]  Luc Montagnier,et al.  T-lymphocyte T4 molecule behaves as the receptor for human retrovirus  LAV , 1984, Nature.

[37]  M. Greaves,et al.  The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus , 1984, Nature.